166 related articles for article (PubMed ID: 26460258)
1. An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.
Maia RC; Bonamino MH; Robaina MC; Amaral N; Bonecker S; Zalcberg IR; Klumb CE
Blood Cells Mol Dis; 2015 Dec; 55(4):347-50. PubMed ID: 26460258
[TBL] [Abstract][Full Text] [Related]
2. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
[TBL] [Abstract][Full Text] [Related]
3. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
Barosi G; Bergamaschi G; Marchetti M; Vannucchi AM; Guglielmelli P; Antonioli E; Massa M; Rosti V; Campanelli R; Villani L; Viarengo G; Gattoni E; Gerli G; Specchia G; Tinelli C; Rambaldi A; Barbui T;
Blood; 2007 Dec; 110(12):4030-6. PubMed ID: 17712047
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!
Fraga GR; Caughron SK
Am J Dermatopathol; 2010 Oct; 32(7):727-30. PubMed ID: 20859081
[TBL] [Abstract][Full Text] [Related]
6. Immunoproteasome Genes Are Modulated in CD34
Di Rosa M; Giallongo C; Romano A; Tibullo D; Li Volti G; Musumeci G; Barbagallo I; Imbesi R; Castrogiovanni P; Palumbo GA
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331228
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
8. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
9. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
10. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Guglielmelli P; Barosi G; Specchia G; Rambaldi A; Lo Coco F; Antonioli E; Pieri L; Pancrazzi A; Ponziani V; Delaini F; Longo G; Ammatuna E; Liso V; Bosi A; Barbui T; Vannucchi AM
Blood; 2009 Aug; 114(8):1477-83. PubMed ID: 19549988
[TBL] [Abstract][Full Text] [Related]
11. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
[TBL] [Abstract][Full Text] [Related]
13. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.
DeLario MR; Sheehan AM; Ataya R; Bertuch AA; Vega C; Webb CR; Lopez-Terrada D; Venkateswaran L
Am J Hematol; 2012 May; 87(5):461-4. PubMed ID: 22389089
[TBL] [Abstract][Full Text] [Related]
14. JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.
Catarsi P; Rosti V; Morreale G; Poletto V; Villani L; Bertorelli R; Pedrazzini M; Zorzetto M; Barosi G;
PLoS One; 2015; 10(1):e0116636. PubMed ID: 25617626
[TBL] [Abstract][Full Text] [Related]
15. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
16. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
17. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
18. JAK2-positive Philadelphia-negative myeloproliferative neoplasms.
Sharma A; Buxi G; Marwah S; Yadav R
Indian J Pathol Microbiol; 2011; 54(1):117-20. PubMed ID: 21393891
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
Barosi G; Poletto V; Massa M; Campanelli R; Villani L; Bonetti E; Viarengo G; Catarsi P; Klersy C; Rosti V
PLoS One; 2013; 8(3):e59791. PubMed ID: 23555782
[TBL] [Abstract][Full Text] [Related]
20. Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature.
Gualco G; Ojopi EB; Chioato L; Cordeiro DL; Negretti F; Bacchi CE
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):291-5. PubMed ID: 20042850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
